Matches in Wikidata for { <http://www.wikidata.org/entity/Q37220464> ?p ?o ?g. }
- Q37220464 description "article científic" @default.
- Q37220464 description "article scientifique" @default.
- Q37220464 description "articolo scientifico" @default.
- Q37220464 description "artigo científico" @default.
- Q37220464 description "artículu científicu espublizáu en 2016" @default.
- Q37220464 description "bilimsel makale" @default.
- Q37220464 description "scientific article published on 15 March 2016" @default.
- Q37220464 description "vedecký článok" @default.
- Q37220464 description "vetenskaplig artikel" @default.
- Q37220464 description "videnskabelig artikel" @default.
- Q37220464 description "vědecký článek" @default.
- Q37220464 description "wetenschappelijk artikel" @default.
- Q37220464 description "wissenschaftlicher Artikel" @default.
- Q37220464 description "наукова стаття, опублікована в березні 2016" @default.
- Q37220464 description "научни чланак" @default.
- Q37220464 description "مقالة علمية نشرت في 15 مارس 2016" @default.
- Q37220464 name "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 name "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 name "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant" @default.
- Q37220464 type Item @default.
- Q37220464 label "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 label "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 label "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant" @default.
- Q37220464 prefLabel "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 prefLabel "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 prefLabel "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant" @default.
- Q37220464 P1433 Q37220464-C164923C-DC74-47E9-BF53-656CC834669E @default.
- Q37220464 P1476 Q37220464-4A177FBB-E9C4-465F-9E90-4EF793D3B92B @default.
- Q37220464 P2093 Q37220464-0F7E92E6-F6F6-49B5-ADC1-D17B90987781 @default.
- Q37220464 P2093 Q37220464-25C1435A-BA2E-4E64-8BBF-F7DD58B4BE52 @default.
- Q37220464 P2093 Q37220464-452C814D-59A2-413D-A9CF-1C03AA61F830 @default.
- Q37220464 P2093 Q37220464-48F86D6E-5839-4706-A5DB-F0E3475A8987 @default.
- Q37220464 P2093 Q37220464-530C651E-03F7-4060-A860-69AB7797FB57 @default.
- Q37220464 P2093 Q37220464-66216841-9DEE-4145-9294-1E24E4C56798 @default.
- Q37220464 P2093 Q37220464-8874F01C-92AF-46AA-BBB6-9FFF10F2F8AC @default.
- Q37220464 P2093 Q37220464-C289FF01-5091-4AE1-966B-24BE7B68D37F @default.
- Q37220464 P2093 Q37220464-C5495ABD-2B30-47F6-A6E6-1FABEDABDD85 @default.
- Q37220464 P2093 Q37220464-C5B7283B-C99F-4A62-8687-3F6C62C4D890 @default.
- Q37220464 P2093 Q37220464-FDACB9BE-EB0C-4B37-9617-4A32A5F9D2E1 @default.
- Q37220464 P2860 Q37220464-0090C12B-D7B6-4530-A8E4-2A6F05129A47 @default.
- Q37220464 P2860 Q37220464-02124808-4E15-48CC-BC79-B6078954B0E5 @default.
- Q37220464 P2860 Q37220464-2F17F10C-CA00-4E2F-AAC7-C58FCBE5408A @default.
- Q37220464 P2860 Q37220464-31D2F083-66EE-4C95-87EE-4571E31B4A59 @default.
- Q37220464 P2860 Q37220464-3690FC68-1CED-44A3-972B-2A9C6BF7F050 @default.
- Q37220464 P2860 Q37220464-45D532BC-690F-41FA-BDB0-1EE0FA7001A5 @default.
- Q37220464 P2860 Q37220464-500969C4-CF1C-4BEC-9B7C-3764B79390E4 @default.
- Q37220464 P2860 Q37220464-56E09DEE-3B2E-45E1-AF8A-CE165BC19A2C @default.
- Q37220464 P2860 Q37220464-5C2F837B-99F7-4210-BD0B-952878ADA1F1 @default.
- Q37220464 P2860 Q37220464-63C0AE5E-F14D-4745-9801-0C4630EFB42B @default.
- Q37220464 P2860 Q37220464-7BA83AEF-EB3E-4C97-B5A7-200C8094AC6C @default.
- Q37220464 P2860 Q37220464-7CA97C11-C65C-4268-86E7-4A0086CD5EAF @default.
- Q37220464 P2860 Q37220464-7D4F900A-9C8B-43AC-AA9C-A36D1F2B4429 @default.
- Q37220464 P2860 Q37220464-8D4CD7C3-5B4D-403F-94E4-A4469393B6ED @default.
- Q37220464 P2860 Q37220464-C08BE560-D53A-4D01-86F7-57A9261AA297 @default.
- Q37220464 P2860 Q37220464-C35A49FB-405E-4BEF-A7D2-2AF396FC56F7 @default.
- Q37220464 P2860 Q37220464-CC1BC421-0177-400F-A11E-F6480A0BCFEF @default.
- Q37220464 P2860 Q37220464-D24C09E3-C2B6-4F94-9DE1-1B3763E6FAE7 @default.
- Q37220464 P2860 Q37220464-DAEE5562-1950-448F-817B-1AE008F9670C @default.
- Q37220464 P2860 Q37220464-E4789D94-A9CD-4A07-8E58-0CD217762444 @default.
- Q37220464 P2860 Q37220464-EAAD7A8B-615F-47E6-84E3-5E58FE808104 @default.
- Q37220464 P2860 Q37220464-FCBA0DF6-88C2-4443-9E34-F63C7433FF44 @default.
- Q37220464 P31 Q37220464-DFAB998E-6A76-440D-93C2-EBB11AB064CC @default.
- Q37220464 P356 Q37220464-A14EFC4C-CCE1-4BB7-9934-830D5D0396DB @default.
- Q37220464 P433 Q37220464-335F1EF2-0F7C-4ACE-97A5-FBD8CA97A2D1 @default.
- Q37220464 P478 Q37220464-9D8BDD31-13AF-4AEF-BD62-A6DB5135038D @default.
- Q37220464 P577 Q37220464-95C28FEC-B8DA-4589-A807-6192CACF1595 @default.
- Q37220464 P5875 Q37220464-0307E872-BE41-4F5C-9187-7682A3692A0D @default.
- Q37220464 P698 Q37220464-B6B21CFB-35B8-4BA5-A114-0D1F4D706ACF @default.
- Q37220464 P932 Q37220464-B86096D9-9A7E-4477-AC52-5A67CB87F63F @default.
- Q37220464 P356 PYW022 @default.
- Q37220464 P698 26979830 @default.
- Q37220464 P1433 Q7742309 @default.
- Q37220464 P1476 "A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia" @default.
- Q37220464 P2093 "David Michelson" @default.
- Q37220464 P2093 "Duane Snavely" @default.
- Q37220464 P2093 "Ellen Snyder" @default.
- Q37220464 P2093 "Erin Mahoney" @default.
- Q37220464 P2093 "Jill Hutzelmann" @default.
- Q37220464 P2093 "Kathryn M Connor" @default.
- Q37220464 P2093 "Nan Jia" @default.
- Q37220464 P2093 "Saheeda Jackson" @default.
- Q37220464 P2093 "Thomas Roth" @default.
- Q37220464 P2093 "W Joseph Herring" @default.
- Q37220464 P2093 "Xin Zhao" @default.
- Q37220464 P2860 Q28142783 @default.
- Q37220464 P2860 Q28272266 @default.
- Q37220464 P2860 Q29615534 @default.
- Q37220464 P2860 Q34226529 @default.
- Q37220464 P2860 Q34285771 @default.
- Q37220464 P2860 Q34607196 @default.
- Q37220464 P2860 Q34628298 @default.
- Q37220464 P2860 Q34727018 @default.
- Q37220464 P2860 Q34852294 @default.
- Q37220464 P2860 Q34915172 @default.
- Q37220464 P2860 Q36018973 @default.
- Q37220464 P2860 Q36430588 @default.
- Q37220464 P2860 Q37522859 @default.
- Q37220464 P2860 Q37565882 @default.
- Q37220464 P2860 Q37772972 @default.
- Q37220464 P2860 Q37977721 @default.